PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2014

Luteolin reduces Alzheimer's disease pathologies induced by traumatic brain injury.

Mouse / TBI

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 24413756 ↗2014Reported benefit

Luteolin reduces Alzheimer's disease pathologies induced by traumatic brain injury.

MouseTBIControlled cortical impactTg2576 (amyloid-beta depositing) and wild-type littermatesMale and female (6 female and 6 male in the main treatment cohort)n = 12 Tg2576 mice for the treatment study (6 luteolin, 6 PBS),…Intraperitoneal (treatment study); oral gavage (biodistribution study)20 mg/kg intraperitoneally for the treatment study; 1.25, 2…Pre-treatment, daily for 15 days before induction of traumatic brain injury

Model: Moderate controlled cortical impact over the left frontoparietal cortex (1.0 mm tip, 1.0 mm impact depth, 6 m/s velocity, 100 ms dwell time)

Traumatic brain injury significantly raised soluble (monomeric) amyloid-beta, activated GSK-3, phospho-tau, TNF-alpha and IL-1 beta at 3 days. Luteolin pre-treatment significantly abolished these increases. Insoluble amyloid-beta was not significantly increased. Total luteolin reached approximately…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.